Express News | Reported Earlier, HUTCHMED Secures Full NMPA Approval For ORPATHYS In China To Treat Advanced MET Exon 14 NSCLC
Hutchmed's Lung Cancer Treatment Wins Chinese Approval
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $26
Private Equity Firms Are HUTCHMED (China) Limited's (LON:HCM) Biggest Owners and Were Rewarded After Market Cap Rose by UK£120m Last Week
Sector Update: Health Care Stocks Edge Higher Premarket Thursday
Express News | HUTCHMED Shares Are Trading Higher After the Company Announced the Divestment of Its 45% Interest in Shanghai Hutchison Pharmaceuticals
